These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1359059)

  • 1. A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine.
    Daniel W; Melzacka M
    J Pharm Pharmacol; 1992 May; 44(5):429-32. PubMed ID: 1359059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional distribution of imipramine, desipramine and specific [3H]desipramine binding sites in the rat brain after acute and chronic treatment with imipramine.
    Daniel W; Danek L; Janczar L; Nocon H; Melzacka M
    J Pharm Pharmacol; 1991 Jan; 43(1):31-5. PubMed ID: 1676056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the route of administration of imipramine on imipramine and desipramine blood levels.
    Rigal J; Albin H; Fança X; Demotes-Mainard F; Vinçon G
    J Clin Psychopharmacol; 1989 Oct; 9(5):364-7. PubMed ID: 2677063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triiodothyronine increases desipramine with changing the concentrations of monoamines, in the brain of rat given imipramine.
    Suzuki S; Yoshida T; Sugita S; Kobayashi A; Nakazawa K
    Eur J Pharmacol; 1993 Feb; 231(2):297-300. PubMed ID: 7681006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine.
    Lemmer B; Holle L
    Chronobiol Int; 1991; 8(3):176-85. PubMed ID: 1794155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of imipramine and desipramine in rat brain regions after single and chronic administration of imipramine.
    Szymura-Oleksiak J; Panas M; Chruściel W
    Pol J Pharmacol Pharm; 1984; 36(1):21-6. PubMed ID: 6462958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic dosage of imipramine in animal experiment: concentrations of imipramine and desipramine in the rat brain after various modes of dosage.
    Melzacka M; Rurak A; Danek L; Daniel W; Vetulani J
    Pol J Pharmacol Pharm; 1985; 37(4):525-32. PubMed ID: 4080646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipramine distribution among red blood cells, plasma and brain tissue.
    Fisar Z; Krulik R; Fuksová K; Sikora J
    Gen Physiol Biophys; 1996 Feb; 15(1):51-64. PubMed ID: 8902557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
    Spina E; Avenoso A; Campo GM; Scordo MG; Caputi AP; Perucca E
    Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of imipramine and desipramine in man after different routes of administration.
    Nagy A; Johansson R
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 290(2-3):145-60. PubMed ID: 1102994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
    Spina E; Pollicino AM; Avenoso A; Campo GM; Perucca E; Caputi AP
    Ther Drug Monit; 1993 Jun; 15(3):243-6. PubMed ID: 8333005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage optimization methods applied to imipramine and desipramine in enuresis treatment.
    Tamayo M; Fernández de Gatta MM; García MJ; Domínguez-Gil A
    J Clin Pharm Ther; 1992 Feb; 17(1):55-9. PubMed ID: 1548314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
    Nguyen HQ; Callegari E; Obach RS
    Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of depression to very high plasma levels of imipramine plus desipramine.
    Garvey M; DeRubeis RJ; Hollon SD; Evans MD; Tuason VB
    Biol Psychiatry; 1991 Jul; 30(1):57-62. PubMed ID: 1892963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The route of administration of imipramine as a factor affecting formation of its metabolite desipramine.
    Daniel W; Adamus A; Melzacka M; Szymura J
    J Pharm Pharmacol; 1982 Oct; 34(10):678-80. PubMed ID: 6128396
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonlinear kinetics of imipramine in low and medium plasma level ranges.
    Sindrup SH; Brøsen K; Gram LF
    Ther Drug Monit; 1990 Sep; 12(5):445-9. PubMed ID: 2293406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of imipramine and desipramine.
    Sallee FR; Pollock BG
    Clin Pharmacokinet; 1990 May; 18(5):346-64. PubMed ID: 2185906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages.
    Daniel W; Adamus A; Melzacka M; Szymura J; Vetulani J
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Nov; 317(3):209-13. PubMed ID: 7322212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis.
    Sato Y; Shibanoki S; Sugahara M; Ishikawa K
    Br J Pharmacol; 1994 Jun; 112(2):625-9. PubMed ID: 8075879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.
    Ciraulo DA; Barnhill JG; Jaffe JH
    Clin Pharmacol Ther; 1988 May; 43(5):509-18. PubMed ID: 3365915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.